Sales Channel Optimization - The offline sales channel optimization is progressing as expected, with significant improvements in channel quality and management capabilities [2] - The company is expanding its offline sales team to establish a solid foundation for long-term operations [2] - The shift from traditional distribution to value-driven sales models aims to enhance profitability and growth potential of offline channels [2][3] Market Competition - The company views strong competitors as catalysts for growth, providing valuable learning experiences [3] - The offline profit margins are substantial, prompting proactive adjustments to adapt to intense market competition [3] Revenue Expectations - The company is optimistic about recovering offline revenue in 2026, having made adequate preparations in 2025 [4] - Continuous efforts will be made to expand the offline market in 2026 [4] Online Sales Performance - The largest online sales platforms are Douyin and Tmall, with both showing similar sales volumes [5] - Other platforms, such as JD.com, have also shown significant growth in 2025 [5] Product Development - The company has high expectations for the upcoming medical product, the seaweed sugar repair patch, which is still in the pre-launch phase [5] - The lactose acid mask launched previously performed excellently in 2025, meeting sales expectations [5] - The company is preparing to submit materials for the approval of a new collagen product, with clinical trials completed [6]

1. Report Industry Investment Rating - No information provided about the industry investment rating. 2. Core Viewpoints of the Report - The company's online sales channels, including those managed by the Shanghai and Hangzhou teams, have improved in terms of personnel, expertise, and operational efficiency, and the online sales performance meets expectations. The company will continue to recruit professionals to enhance operational efficiency [21]. - The proportion of non - patch products is increasing year by year, and the company will continue to diversify product forms to meet consumer needs [21]. - The online sales proportion has exceeded the offline proportion. The company's offline market has great potential, and it will increase efforts to expand the offline market in the future [21][23]. - The ROI of the Douyin platform improved significantly in 2025 through refined operations, and the company aims to further improve and stabilize it [21]. - In 2025, the company launched dozens of new products, including the Centella asiatica series, the oil - based skin - care series, etc. [23]. - The company has set internal sales targets for 2026 but has no publicly available performance guidance [23]. - The company's recombinant type III humanized collagen freeze - dried fiber has completed clinical trials, and the injection - type recombinant type III humanized collagen gel plans to start clinical trials this year [23]. 3. Summary by Directory 3.1 Research Basic Situation - The research object is Fuerjia. The reception time was on March 17, 2026. The listed company's reception personnel included Director and Board Secretary Deng Baijiao, Securities Affairs Representative Wu Hong, and Investor Relations Management IR Qi Xinxin [16]. 3.2 Detailed Research Institutions - The research institutions include Guohai Securities Co., Ltd. (represented by Li Yuchen), Rongtong Fund Co., Ltd. (represented by Ma Chunxuan), and Caitong Securities (represented by Yang Jiarui). Guohai Securities Co., Ltd. participated twice [17]. 3.3 Research Institution Proportion - No information provided about the research institution proportion. 3.4 Main Content Information - **Sales channels**: The Shanghai team is responsible for interest e - commerce platforms like Douyin, and the Hangzhou team is responsible for shelf e - commerce platforms like Tmall. The offline sales channels are divided into three teams for CS & KA channels, professional channels, and OTC channels [21]. - **Non - patch product proportion**: The proportion of non - patch products is increasing, and the company will continue to diversify product forms [21]. - **Online - offline proportion trend**: Initially, the offline proportion was higher, but now the online proportion has exceeded the offline proportion [21]. - **Douyin ROI**: The ROI on Douyin improved significantly in 2025, and the company aims to further improve and stabilize it [21]. - **New products in 2025**: Dozens of new products were launched, such as the Centella asiatica series, the oil - based skin - care series, etc. [23]. - **Performance guidance**: The company has set internal sales targets for 2026 but has no publicly available performance guidance [23]. - **Medical aesthetic product planning**: The recombinant type III humanized collagen freeze - dried fiber has completed clinical trials, and the injection - type recombinant type III humanized collagen gel plans to start clinical trials this year [23]. - **Offline market outlook**: The offline market has great potential, and the company will increase efforts to expand it in the future [23].

Group 1: Company Operations and Changes - In 2025, the company optimized its offline sales channels and improved its management team, which aligned with expectations [2] - The offline market is crucial for the company's long-term development, necessitating adjustments for better profitability [2] - The company aims to maintain stable pricing across all channels, managing price through promotions during peak sales periods [3] Group 2: Sales Channel Adjustments - The optimization led to a reduction in the number of distributors, focusing on higher quality partnerships with service-oriented distributors [3] - The company expects positive performance in offline sales for 2026 due to improved channel quality and team enhancements [3] Group 3: Product Development and Future Plans - The medical aesthetics channel remains a key focus, with plans to increase R&D efforts and accelerate product launches [3] - Progress is being made on injectable products, including a humanized collagen product that has completed clinical trials and is preparing for submission [3]

Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Investment Rating - The industry investment rating is "stronger than the market," indicating that the industry index is expected to outperform the market by more than 5% within the next six months [27]. Core Insights - The report highlights that the upstream sectors are favored by capital, with a focus on rigid demand segments within the consumer industry [4]. - The tourism sector shows significant growth potential, with record-high travel and spending during the Spring Festival, suggesting a robust recovery in consumer demand [8]. - The beauty industry is experiencing steady growth, with a recommendation to monitor leading companies that adapt quickly to market changes [4]. - The food and beverage sector, particularly alcoholic beverages, is seeing a decline in profits for many companies, but leading firms are expected to gain market share due to superior brand management [4][10]. - The report notes a shift in consumer preferences towards healthier options in the food and beverage sector, with opportunities in the home dining market and dairy products [4][22]. Summary by Sections Market Performance - The Shanghai Composite Index and the CSI 300 Index increased by 1.98% and 1.08% respectively, driven by sectors such as steel, non-ferrous metals, and chemicals [7]. - The consumer sector showed mixed performance, with agriculture, textiles, and light manufacturing outperforming the CSI 300, while retail, home appliances, food and beverage, and media sectors lagged behind [7]. Social Services - The report emphasizes the importance of companies that respond positively to changing consumer demands, particularly in tourism and beauty sectors [4][8]. - The Spring Festival saw 596 million domestic trips and total spending of 803.48 billion yuan, marking a significant increase from the previous year [8]. Food and Beverage - Alcohol - The report indicates that many liquor companies are experiencing deeper profit declines, but leading firms are expected to maintain or grow their market share due to strong brand management [4][10]. - The high-end liquor market remains resilient, while the mid-range segment continues to expand nationally [4]. Food and Beverage - Consumer Goods - The report highlights a rigid demand for consumer goods during the Spring Festival, with a trend towards healthier gift options [4][22]. - Companies like Guoquan are noted for their strong market position in the home dining segment, with ongoing expansion plans [4]. Media - The 2026 Spring Festival box office totaled 5.752 billion yuan, a year-on-year decline of 39.5%, indicating challenges in the media sector [14]. - The report suggests that the media industry is facing significant headwinds, particularly in ticket sales and audience engagement [14].

Product Structure - The company's products are mainly divided into two categories: medical devices and functional skincare products [2] - Non-patch products include various forms such as water, essence, lotion, spray, lyophilized, and single-use essence [2] Non-Patch Product Revenue - The revenue share of non-patch products is continuously increasing following the establishment of the Shanghai R&D center, which has accelerated the speed of new product launches [2] Medical Device Progress - The company is making significant progress with three types of medical devices, including recombinant type III humanized collagen protein lyophilized fibers and dressings, with clinical trials completed for the former [3] - The injectable recombinant type III humanized collagen protein gel is expected to start clinical trials this year [3] Pricing Stability - The pricing situation for the company's products is stable, with overall price differences across channels being controllable [3] - Price fluctuations among mainstream channels remain within a reasonable range, with promotional strategies employed to balance sales and pricing during peak periods [3] Aesthetic Medicine Strategy - The company is strategically entering the aesthetic medicine sector due to its pharmaceutical background, aligning medical device products with existing offerings [3] - The company is monitoring potential acquisition targets in the aesthetic medicine field and will adhere to regulatory disclosure obligations for any developments [3] Dividend Policy - The company has maintained a positive attitude towards returning profits to investors through cash dividends since its listing, although specific dividend amounts will depend on performance and financial planning [3] Equity Incentives - The company has plans for equity incentives as the management team evolves, with intentions to disclose specific details in future announcements [3]

Core Insights - The Chinese medical aesthetics industry has surpassed 300 billion yuan, with the light medical aesthetics market expected to grow at a compound annual growth rate (CAGR) of over 20% in the next five years, becoming the mainstream segment by 2024 [1] - Injection projects, as the core growth engine of light medical aesthetics, have seen their market size grow from 25.7 billion yuan in 2018 to 67 billion yuan in 2023, with a CAGR of 21.1%, projected to reach 147 billion yuan by 2027 [1] - The industry faces challenges such as rapid market changes driven by consumer preferences and increasing competition, necessitating innovation in material research to build competitive barriers [1] Market Dynamics - In 2024, the market share of injection materials is projected to be approximately 36% for hyaluronic acid, 29% for botulinum toxin, 19% for collagen, and 16% for regenerative materials [3] - The competition in the hyaluronic acid market has intensified, leading to revenue declines for major companies like Huaxi Biological and Aimeike, with revenue drops of 18.36% and 21.49% respectively in the first three quarters of 2025 [3][4] - In contrast, the recombinant collagen market is rapidly growing, with a projected CAGR of 44.93%, expected to reach 58.57 billion yuan by 2025 [3] Innovation and Product Development - Companies are accelerating new product launches to capture market opportunities, with Huaxi Biological introducing compliant products for facial skin improvement and other companies like Jinbo Biological launching innovative recombinant collagen products [5] - The emergence of new materials such as alginate and hydroxyapatite is set to enrich the market supply, with several products receiving regulatory approval in 2025 [6] Regulatory Environment - The industry is experiencing a shift towards compliance, with increased regulatory scrutiny leading to a "survival of the fittest" scenario, pushing medical aesthetic institutions to accelerate compliance transformations [2] - Despite the growth in compliant products, issues such as illegal operations and counterfeit products remain prevalent, posing risks to consumer safety [11][12] Pricing and Market Structure - The supply expansion has led to a restructuring of interests within the industry, with upstream manufacturers and downstream medical institutions engaged in pricing power struggles [8][9] - New platforms like Xinyang are disrupting traditional pricing models by significantly reducing costs through digitalization and centralized procurement, indicating a shift from a seller's market to a buyer's market [9][10] Future Trends - The industry is expected to evolve towards a more transparent and competitive landscape, with a focus on product and scenario-driven strategies, comprehensive treatment solutions, and enhanced consumer awareness [10] - The ongoing regulatory efforts and market dynamics suggest that the medical aesthetics industry is moving towards a more mature and compliant operational model, emphasizing innovation and safety [14]

Core Viewpoint - The article highlights the rapid rise of Jinbo Biotechnology, a company founded by Yang Xia, in the biopharmaceutical industry in Shanxi, showcasing its innovative achievements in recombinant collagen products and its significant market presence after listing on the Beijing Stock Exchange [1][8]. Company Overview - Jinbo Biotechnology was established in 2008 by Yang Xia, who aimed to develop synthetic collagen to reduce the high costs and improve the success rates of organ transplants [3][4]. - The company successfully developed the world's first recombinant type III humanized collagen gel without cross-linking agents, marking a significant technological breakthrough [11][19]. Financial Performance - From 2021 to 2024, Jinbo Biotechnology's revenue increased from 233 million yuan to 1.443 billion yuan, and after its listing in July 2023, the company's market capitalization approached 30 billion yuan, making it a leading stock on the Beijing Stock Exchange [8][19]. Product Development - Jinbo's recombinant type III humanized collagen has identical amino acid sequences to natural type III collagen and is used in various applications, including advanced implant materials and skincare products [6][11]. - The company has developed a range of products, including the "Wei Yi Mei" series, which became the first injectable-grade human collagen product to be commercialized globally [6][8]. Technological Innovation - Jinbo Biotechnology emphasizes original innovation, having established a fully integrated production facility for humanized collagen products, utilizing advanced technologies such as industrial IoT and AI [11][19]. - The company has participated in setting industry standards for recombinant collagen, further solidifying its leadership position in the global market [13][19]. Strategic Partnerships - In June 2023, Jinbo Biotechnology attracted significant investment from strategic partners, including Nongfu Spring and Wantai BioPharma, indicating strong confidence in the company's growth prospects [18]. - The collaboration aims to enhance the company's capabilities and expand its market reach, particularly in the health and beauty sectors [18][19]. Future Outlook - Jinbo Biotechnology plans to continue advancing its research in recombinant collagen technology and expand its product offerings in the healthcare and life care sectors, aiming to become a leading innovative biopharmaceutical company [19][21].

Investment Rating - The report suggests to pay attention to Jinbo Biological's ongoing developments in the collagen protein application field, indicating a positive outlook for the company [1] Core Viewpoints - Jinbo Biological is actively responding to the demand in China's health industry by expanding its product matrix. The company has made significant moves recently, including the launch of new products and strategic partnerships [2][5] - The company has successfully registered its "recombinant type III humanized collagen freeze-dried fiber" as a pharmaceutical excipient, marking a major breakthrough in high-end biomedical materials [7] - Jinbo Biological's functional skincare brands have shown impressive sales growth during the recent "Double Eleven" shopping festival, with a notable increase in revenue from its proprietary brands [12] - The overall market for consumer services on the Beijing Stock Exchange has seen a median price increase of 2.14% in stock prices, indicating a positive trend in the sector [15][18] - The TTM median price-to-earnings ratio for the broader consumer industry has increased to 56.3X, reflecting a growing valuation in the sector [27][30] Summary by Sections Jinbo Biological's Expansion - Jinbo Biological is expanding its product applications in response to the health industry demand, with a focus on collagen products and strategic partnerships with companies like Yangshengtang [2][10] - The company has established a national-level intellectual property operation center for functional proteins, enhancing its competitive edge in the recombinant collagen market [5][6] Market Performance - The median stock price change for consumer service companies on the Beijing Stock Exchange was +2.14%, with 31 out of 39 companies experiencing stock price increases [15][18] - The total market capitalization for consumer service companies rose from 1140.72 billion to 1143.84 billion, indicating a healthy market environment [20][22] Industry Valuation - The TTM median price-to-earnings ratio for the consumer sector has increased from 55.1X to 56.3X, suggesting a positive valuation trend [27][30] - Specific sectors such as food and beverage, as well as professional technical services, have also seen increases in their TTM median price-to-earnings ratios, indicating overall growth in the consumer market [29][32] Announcements - The successful launch of a 150,000 tons/year n-butane maleic anhydride production facility by Ruihua Technology demonstrates advancements in production technology and reinforces its leading position in the industry [35][37]